Guggenheim analyst Subbu Nambi initiated coverage of Akoya Biosciences with a Neutral rating and no price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKYA:
- Akoya Biosciences price target lowered to $9 from $14 at Stephens
- Akoya Biosciences sees FY23 revenue $95M-98M, consensus $96.74M
- Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya Biosciences reports Q3 EPS (26c), consensus (37c)
- Akoya Biosciences to showcase spatial biology 2.0 solutions